Mutations in myostatin (GDF8) cause marked increases in muscle mass, suggesting that this
transforming growth factor‐β (TGF‐β) superfamily member negatively regulates muscle …

Genetic deletion of Myostatin, a member of the Transforming Growth Factor-beta family of
signalling molecules, resulted in excessive growth of skeletal muscle. It demonstrated the …

Background Myostatin inhibition is a promising therapeutic strategy to maintain muscle mass
in a variety of disorders, including the muscular dystrophies, cachexia, and sarcopenia …

Myostatin is a secreted protein that negatively regulates skeletal muscle mass determining
both muscle fiber number and size. The myostatin pathway is conserved and regulates …

Inhibition of myostatin signalling or its biological activity has recently emerged as a potential
remedial approach against muscle wasting and degenerative diseases such as muscular …

Myostatin is a negative regulator of muscle mass. Important advances in our understanding
of the complex biology of this factor have revealed the therapeutic potential of antagonizing …

Increasing the size and strength of muscles represents a promising therapeutic strategy for
musculoskeletal disorders, and interest has focused on myostatin, a negative regulator of …

Myostatin is an endogenous inhibitor of muscle conserved across diverse species. In the
absence of myostatin, there is massive muscle growth in mice, cattle, and humans. Previous …

In addition to gene correction therapy and cell transplantation techniques, multidisciplinary
approaches to drug discovery and development offer promising therapeutic strategies for …

Many growth factors are intimately bound to the extracellular matrix, with regulated
processing and release leading to cellular stimulation. Myostatin and GDF11 are closely …